Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sanwa Kagaku Files SHPT Med for Japan Approval
August 26, 2020
- Drug Makers Taking Mixed Disclosure Policies for Coronavirus Infections
August 25, 2020
- Takeda to Sell Japan OTC Biz to Blackstone, Weber Says It’s the Right Choice
August 25, 2020
- Takeda to Offload Japan OTC Biz to Blackstone for 242 Billion Yen
August 24, 2020
- Japan Drug Makers’ Q1 Profit Surges on Voluntary Bans on Doctor Calls: Jiho Tally
August 24, 2020
- Japan Approves CureApp’s Smoking Cessation Apps
August 24, 2020
- Long-Term Prescriptions Up for Expectorants, Bronchodilators amid COVID-19 Emergency: Survey
August 24, 2020
- 4 Drug Makers Flag GLP-1 Use for “Weight Loss” after Diabetes Society Warning
August 24, 2020
- BMS Introduces New Corporate Brand in Japan
August 21, 2020
- Viltepso Now Available in US: Nippon Shinyaku
August 21, 2020
- 4 Add’l Products Recalled over Flawed Testing at Kyowa CritiCare
August 20, 2020
- Boehringer’s Ofev Already Hits Japan Peak Sales Outlook, Momentum Likely to Continue with New Indications
August 20, 2020
- Type 2 Diabetes, Essential Hypertension Most Common Comorbidities in Patients Who Died from COVID-19
August 19, 2020
- ASKA to Snap Up 24.9% Stake in Vietnam Drug Maker
August 19, 2020
- US FDA Accepts Myovant’s Relugolix Triple Combo for Review in Uterine Fibroids
August 19, 2020
- Novo to Skip August Listing for 1st Oral GLP Agent Rybelsus
August 18, 2020
- Pfizer Japan Takes Generic Contenders to Court over Lyrica Patent
August 18, 2020
- Takeda to Introduce Early Retirement Program for Japan Staffers
August 18, 2020
- Fujifilm to Make Antigen for Novavax’s COVID-19 Vaccine for UK Govt
August 18, 2020
- Japan Pharma Market Down 2.5% in April-June: IQVIA
August 18, 2020
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…